TG Therapeutics reported $260.53M in Current Liabilities for its fiscal quarter ending in September of 2026.





Current Liabilities Change Date
AbbVie USD 43.1B 1.46B Sep/2026
Alaunos Therapeutics USD 864K 269K Jun/2026
Amgen USD 23.23B 2.27B Sep/2026
Ardelyx USD 127.8M 4.42M Sep/2026
Arrowhead Research USD 311.34M 27.99M Sep/2026
Bayer EUR 29.4B 2.87B Sep/2026
Biogen USD 3.9B 18.7M Sep/2026
Corcept Therapeutics USD 177.68M 23.87M Sep/2026
Curis USD 14.97M 898K Mar/2026
Gilead Sciences USD 12B 982M Sep/2026
J&J USD 55.46B 562M Sep/2026
Karyopharm Therapeutics USD 117.3M 25.24M Mar/2026
Novartis USD 32.52B 777M Sep/2026
Novavax USD 329.84M 729K Sep/2026
PTC Therapeutics USD 776.08M 5.01M Sep/2026
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Regeneron Pharmaceuticals USD 6.2B 671.5M Sep/2026
Roche Holding CHF 28.85B 846M Jun/2026
TG Therapeutics USD 260.53M 7.97M Sep/2026
Verastem USD 66.84M 5.42M Mar/2026
Vertex Pharmaceuticals USD 5B 1.06B Sep/2026